Andrew Reardon, Chief Legal Officer and Secretary of Ligand Pharmaceuticals, has made notable stock transactions, including the acquisition of 5,000 shares at a price of $52.27 each. This acquisition, reported on November 4, 2026, is significant as it underscores Reardon's ongoing commitment to the company and its future prospects.

Ligand Pharmaceuticals, a company incorporated in Delaware, is primarily involved in the pharmaceutical preparations sector. The company operates under the Central Index Key (CIK) 0000886163 and has a fiscal year ending on December 31. Recent filings indicate that Reardon has been active in the market, with multiple transactions reported in the past months.

According to the filing dated November 4, 2026, Reardon executed several transactions on November 2, 2026. He acquired 5,000 shares of common stock through an employee stock option at the exercise price of $52.27. Additionally, he sold a total of 2,318 shares in various transactions at prices ranging from $306.62 to $323.14. Following these transactions, he retains a total of 32,914 shares of the company.

The filing notes that these transactions were made pursuant to a written trading plan adopted by Reardon on June 4, 2026, in accordance with Rule 10b5-1. This plan allows for structured buying and selling of shares, which can help mitigate the risks associated with market timing.

These transactions may affect various stakeholders, including investors and analysts watching Ligand Pharmaceuticals' stock performance. The pharmaceutical preparations sector is highly competitive, and Reardon's actions may signal confidence in the company's direction and strategy.

The filing does not specify what actions may follow these transactions, leaving the market to speculate on potential future developments.